Life Science Intelligence/Enterprise module

Everything that moves a molecule's value is public. None of it is in one place.
Now it is.

Patent and exclusivity dates, trial completions, FDA action dates, and the federal funding and procurement that name the molecule, matched and dated on one runway, so you know what is expiring, what is moving, and who is paying.

For healthcare investors, M&A advisors, corporate development, and business development teams evaluating a molecule, a sponsor, or a category.
What is expiringPatent cliffs, exclusivity expiry, and generic entry windows from the register edition, with today marked.
What is movingTrial completions and FDA action dates on the same line, with the cascade that tends to follow an action.
Who is payingFederal funding and procurement that names the molecule, by agency, kept separate from the sponsor's own receipts.
2,367
Molecules
122
Sponsor families
3,123
Active trials
86
Runway dates in 12 months
patentexclusivitytrialaction
Scroll
01 · What is expiring

Six molecules. One line of time.

Patents from the register edition, exclusivity with its expiry, generic entry windows, trial completions, action dates, and the public notices that name the class. Today is the teal line. Everything to its right is dated in a public record.

Runway board · 6 molecules on your watch · register edition Aug 2026
patentexclusivitytrialactionnotice
20262027202820292030
Long-acting antiviralexclusivity to Jan 2028
31 · $86.4Mreferencing awards
Oral anticoagulantgeneric entry window Jun 2027
12 · $18.1Mreferencing awards
GLP-1 injectablepediatric exclusivity Aug 2027
44 · $212Mreferencing awards
Oncology biosimilarapproved Sep 2026
3 · $4.0Mdownstream notices
Inhaled corticosteroidexclusivity to Sep 2027
0no open awards
CAR-T, hematologicorphan exclusivity to 2031
19 · $58.6Mreferencing awards
hover a marker for the record · dates from the register edition, the trial registry, and the action history · rejected and quarantined rows excluded · today marked in teal
02 · What is moving

An action becomes a chain.

A regulatory action is the start of a sequence the record already contains: the label, the register, the notices that follow, the awards that name the class. The module reads the chain with the lag observed at each step.

Regulatory action
Biosimilar approval, oncology
The action of record, with the application it was filed under and the product it concerns.
2 Sep 2026 · day 0
Label and register
Listing, reference product
The label lands; the register edition carries the new product beside the incumbent's patents and exclusivity.
+21 days · median on 38 observed cascades
Notices
3 procurement notices
Public buyers open solicitations naming the class. Each notice is keyed to the agency and, where it exists, the program.
+64 days · median · n=38
Awards
Referencing awards
Awards that name the molecule or its class. Read as exposure; attributed to the recipient of record, never to the sponsor by inference.
+7 months · median · IQR 5 to 11
03 · Who is paying

Two measures. Never one number.

A molecule's government exposure and a sponsor's receipts are different claims with different bases. The module reports both, labels which is which, and never adds them.

$86.4M
referencing awards · 12 months · n=31
Referenced
31 · $86.4M
Awards that name the molecule. Government exposure around it, by agency and lane.
own n · never summed with receipts
Attributed
$4.2M · n=7
The sponsor's own receipts, matched on the recipient of record through resolved aliases.
alias-recipient basis · receipts only
Referencing awards by agency · 12 monthsopen in capital flow
NIH, NIAID
$41.2M · 14
HHS, BARDA
$22.9M · 6
DoD, DHA
$9.1M · 4
VA
$7.0M · 5
CDC
$6.2M · 2
58%funder lane · research awards
27%buyer lane · procurement
15%untyped · shown as untyped
04 · How it links

Every link says what kind of claim it is.

Most graph products draw a line between two things and leave you to guess what it means. Life Science Intelligence draws three kinds of line, and money only travels along one of them. A sponsor's receipts and a molecule's mentions are never added together, and a tagged association is never mistaken for attribution.

Attributedsolid gold
The relationship of record: money received, action taken, registry entry. Figures may aggregate along it.
Sponsor receives award. Trial studies molecule. Action filed under product. Award awarded by agency.
Referenceddashed teal
The record names the object. A separate measure with its own n, shown as references, never summed with receipts.
Molecule referenced in award. 31 awards name the molecule; that is exposure, not the sponsor's income.
Associateddotted grey
Co-occurrence in a tagged set. Navigation only. No figure crosses it, ever.
Sponsor associated with molecule. You can walk the link. Nothing is totaled through it.
L1
No transit across associated. No sum, count, or figure crosses an associated edge.
L2
Attributed and referenced never combine. Receipts and references are separate measures with separate n.
L3
Provenance on every edge. Source record, method, lexicon or edition, and n where aggregated.
L4
Rejected rows are non-objects. Rows that fail the reject or quarantine rules never become objects or edges.
L5
Versions are pinned, not implied. Register edition, lexicon version, pick rule. As-of reads from those pins.
05Workbench

Objects left. Links center. Evidence right.

Select any object and the picture redraws around it with the edge grammar visible. The dossier on the right serves the exclusivity runway, government exposure with the funder and buyer split, safety actions, and the provenance footer. Click a node to walk, double-click to expand.

app.svatantra.ai / life-sciences / workbench
Svatantra
Ent
Molecules2,367
Long-acting antiviral
Fixed-dose combination
Protease inhibitor, boosted
Sponsors122
Sponsor parent A
Sponsor parent B
Trials3,123
Molecule trials (12)
Regulatory actions
Approvals and supplements
Patents and exclusivity
Register, Aug 2026 edition
Awards
Referencing awards (31)
Agencies
NIH, NIAID
HHS, BARDA emerging
LinksTimelineTableBoard
$4.2M n=7 attributed 31 refs referenced tagged set - no rollup 12 trials 9 actions 4 patents 2029 Moleculelong-acting antiviral Sponsorparent Awards31 referencing AgencyNIH, NIAID Trials12 active Actions9 approvals Runwayregister
attributed · figures aggregate
referenced · own measure
associated · navigation only
Long-acting antiviral
molecule · lexicon v3 pinned · label and structure on record
LabelStructure12 trials9 actions

Exclusivity runway

Register, Aug 2026 edition · patents gold, exclusivity green
today
Apr 2027
Jan 2028
Oct 2029
Nearest future dateApr 2027
Future patents / exclusivity4 / 2

Government exposure

Molecule references · a referencing measure, not sponsor receipts
Referencing awards31
Value$86.4M
funder 58% · buyer 27% · untyped 15%
NIH, NIAID$41.2M · 14
HHS, BARDA$22.9M · 6
DoD, DHA$9.1M · 4

Safety actions

No safety actions in Svatantra's sources as of 10 Sep 2026.
basis: alias-recipient (receipts) / molecule tag (references)
lexicon v3 · pick rule v4 · register edition 2026-08
reject and quarantine rows excluded · figures carry n
1234
01
Object railEvery object type the module serves, with live counts. Confidence tiers ride the item, not a footnote.
02
Links pictureForce-directed, drag to rearrange, click to walk, double-click to expand. The edge grammar is visible on every line.
03
Exclusivity runwayPatents and exclusivity from the register edition, with today marked and the nearest future date first.
04
Government exposureReferencing awards by agency with the funder and buyer split. Labeled as a referencing measure, never as sponsor receipts.
06Board and canvas

Build the case by dragging. Every card fills itself from the record.

Drop a molecule, a sponsor, an agency, or a trial set onto the board. The card fills itself from the record and the ties draw between anything already linked, each tie labeled with its figure, its basis, and its n. Suggested links arrive as ghost cards you keep or dismiss. Name the board, save it, share it with an expiry, or open it as a free canvas.

app.svatantra.ai / life-sciences / board
Svatantra
Ent
Export memoDeadlines (.ics)Concentration lensAsk the boardas of: register 2026-08 · lexicon v3
attributedreferencedassociated
Live: drag the cards
molecule
Long-acting antiviral
RunwayApr 2027
References31 · $86.4M
sponsor
Sponsor parent A
Receipts$4.2M · n=7
Aliases6
agency
NIH, NIAID
Referencing14 · $41.2M
Open notices2
trial set
Molecule trials
Active12
Phase 34
suggested
+ 3 links
2 agencies · 1 sponsor
KeepDismiss
Served rows only. Every figure on this board carries basis and n. Associated ties carry no figure. Board "Antiviral runway 2027" saved · shared with expiry 30 Sep · 2 notes
1234
01
Tie labelsEvery tie between pinned objects carries its figure, its basis, and its n.
02
Attributed tieSponsor to agency: receipts, alias-recipient basis. The only tie money travels along.
03
Ghost linksSuggested links arrive as ghost cards. Keep or dismiss; nothing lands unasked.
04
ToolbarExport memo, deadlines as .ics, concentration lens, ask the board (served figures only, cited), as-of pins.
07Dossier

One molecule, fully unpacked.

The dossier is the evidence behind every card. Runway dates from the register edition, referencing awards by agency, active trials with sponsors, the action history, safety actions where they exist, and the seven-layer ledger at the foot of the page.

app.svatantra.ai / life-sciences / molecule
Svatantra
Ent
Life Science Intelligence · molecule · dossier
Long-acting antiviral
molecule · label and structure on record · 6 sponsor aliases resolved · lexicon v3
$86.4M
Referencing awardsn=31 · 12 months
12
Active trials4 in phase 3
Apr 2027
Nearest runway dateexclusivity
Exclusivity runway · register, Aug 2026 editionas of
today
Apr 2027 · patent
Jan 2028 · exclusivity
Mar 2029 · patent
Oct 2029 · patent
Active trials · registry, reject-filteredall 12
TrialPhaseSponsorEnrolledPrimary completion
Long-acting regimen, treatment-naive adults3Sponsor parent A1,240Mar 2027
Switch study, virologically suppressed3Sponsor parent A860Jun 2027
Pediatric dosing, 12 to 182Academic network214Nov 2026
Pre-exposure, quarterly injection3Federal institute3,300Sep 2027
Government exposure · referencing awards by agencyfunder 58% · buyer 27%
NIH, NIAID
$41.2M · 14
HHS, BARDA
$22.9M · 6
DoD, DHA
$9.1M · 4
VA
$7.0M · 5
CDC
$6.2M · 2
Regulatory actions · 9cascade
14 Aug 2026
Supplement approved · pediatric indication
02 Jun 2026
Label change · dosing interval
19 Feb 2026
Supplement approved · new formulation
08 Nov 2025
Approval · long-acting injectable
Safety actions
No safety actions in Svatantra's sources as of 10 Sep 2026.
Sponsor familyassociated · no rollup
Sponsor parent A
6 aliases · receipts $4.2M · n=7 · attributed
open
Sponsor parent B
co-development · tagged set only
open
Evidence ledger · 7 layers
1Sourceevery row links to the public record it came from
2Statisticaln on every figure; receipts and references never summed
3Methodologyalias-recipient match v2 · molecule tag v3 · register edition 2026-08
4Outcome loggingrunway dates logged; register re-read monthly
5ConfidenceHIGH on receipts, MODERATE on references, EMERGING on one agency lane
6Dissent1 referencing award names a substitute molecule in the same lot
7Auditfull chain reconstructible · last recompute 10 Sep 06:32 UTC
09 · Evidence

Seven layers on every figure.

Nothing on a runway, a board, or a memo is computed on the fly from a model. It is served from the record, with its basis and its n.

1Source attribution
2Statistical transparency
3Methodology disclosure
4Outcome logging
5Confidence framework
6Dissenting evidence
7Audit trail

Bring a molecule. Leave with the runway.

A 30-minute walkthrough on your own molecules and markets. Enterprise access includes the module, the board, and the memo export.